![](/templates/dist/images/line_c.jpg)
![](/templates/dist/images/line_arrow.jpg)
AmoyDx® HRD Focus Panel
![CE](/upfiles/property/202401/1705648520230.jpg)
Leveraging proprietary HANDLE technology, the Genomic Scar Score (GSS) algorithm, and the AmoyDx NGS Data Analysis System (ANDAS), the HRD Focus assay can be seamlessly integrated into your laboratory workflow.
![卵巢](/upfiles/property/202401/1704865833185.png)
AmoyDx® HRD Complete Panel
A comprehensive homologous recombination deficiency (HRD) test to accelerate PARPi clinical research
![乳腺](/upfiles/property/202401/1706597222117.png)
![卵巢](/upfiles/property/202401/1704865833185.png)
AmoyDx® Master Panel
A leading CGP assay that encompasses a wide array of genomic signatures, including HRD, MSI, and TMB, thereby advancing biomarker identification and cancer treatment research across various tumor types.
![肺](/upfiles/property/202401/1704331605695.png)
![结直肠](/upfiles/property/202401/1704331598408.png)
![甲状腺](/upfiles/property/202401/1704331614094.png)
![乳腺](/upfiles/property/202401/1706597222117.png)
![卵巢](/upfiles/property/202401/1704865833185.png)
AmoyDx® BRCA Pro Panel
![CE](/upfiles/property/202401/1705648520230.jpg)
This panel enables the detection of germline/somatic SNVs/Indels as well as germline large rearrangements (LRs) from either whole blood or FFPE tissue samples.
![乳腺](/upfiles/property/202401/1706597222117.png)
![卵巢](/upfiles/property/202401/1704865833185.png)
AmoyDx® HANDLE Classic NGS Panel
![CE](/upfiles/property/202401/1705648520230.jpg)
The AmoyDx HANDLE Classic Panel encompasses 40 key solid tumor genes, enabling the detection of common mutations to support clinical therapeutic decisions with rapid turnaround time (TAT).
![肺](/upfiles/property/202401/1704331605695.png)
![结直肠](/upfiles/property/202401/1704331598408.png)
![甲状腺](/upfiles/property/202401/1704331614094.png)
AmoyDx® Essential NGS Panel
![CE](/upfiles/property/202401/1705648520230.jpg)
The assay is tailored to detect prevalent mutations in 10 genes: EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET, in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), using FFPE or Liquid Biopsy samples.
![肺](/upfiles/property/202401/1704331605695.png)
![结直肠](/upfiles/property/202401/1704331598408.png)